Roflumilast (Zoryve) vs Roflumilast (Zoryve foam)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: PDE4 · full Psoriasis pipeline

Roflumilast (Zoryve)

Marketed by Arcutis Biotherapeutics and partners

Approved in Psoriasissmall molecule
Partial signal

NCT06648772 · Phase 3 · completed

The study randomly assigned 190 participants to roflumilast cream or vehicle cream and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinical psoriasis severity measure, but whether that endpoint was met cannot be determined because results are not available.

Next expected readout: July 2027 · NCT07725822 (registry estimate)

Reported efficacy

Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%) (met)

Result source: NCT04211389

Roflumilast (Zoryve foam)

Marketed by Arcutis Biotherapeutics and partners

Approved in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRoflumilast (Zoryve)Roflumilast (Zoryve foam)
PASI 7541.6% vs 7.6%+34 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 39% vs 5.3% 0.3% cream · wk 8 · n 264 · Phase 3 · secondary NCT04211389
  • 31.3% vs 13.2% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 23% vs 13.2% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 24.1% vs 9.6% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 22.2% vs 9.6% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 13.3% vs 10.5% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 7.6% vs 10.5% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258
  • 34.1% vs 16% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 31.1% vs 16% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
50.1% vs 16.8%+33.3 vs placebo0.3% foam · wk 8 · n 281NCT05028582
PASI 9022.4% vs 2.3%+20.1 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 15.5% vs 2% 0.3% cream · wk 8 · n 290 · Phase 3 · secondary NCT04211389
  • 20.6% vs 7.8% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 13.7% vs 7.8% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
  • 16.9% vs 6% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 7.4% vs 6% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 14.3% vs 3.2% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 2.3% vs 3.2% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 6% vs 2.3% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 1.3% vs 2.3% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258
—Not reported
PASI 100—Not posted · NCT06648772—Not reported
sPGA 0/1—Not posted · NCT06648772—Not reported
DLQI, change-2.6 vs -1.4−1.2 vs placebo0.3% · wk 12 · n 58NCT03638258
7 other results
  • -4.2 vs -1.4 0.15% · wk 12 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.6 0.3% · wk 8 · n 58 · Phase 2 · secondary NCT03638258
  • -3.5 vs -1.6 0.15% · wk 8 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.8 0.3% · wk 6 · n 58 · Phase 2 · secondary NCT03638258
  • -3.1 vs -1.8 0.15% · wk 6 · n 60 · Phase 2 · secondary NCT03638258
  • -2.2 vs -1.9 0.3% · wk 4 · n 58 · Phase 2 · secondary NCT03638258
  • -2.3 vs -1.9 0.15% · wk 4 · n 60 · Phase 2 · secondary NCT03638258
—Not reported

PASI 75

Roflumilast (Zoryve)
41.6% vs 7.6%+34 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 39% vs 5.3% 0.3% cream · wk 8 · n 264 · Phase 3 · secondary NCT04211389
  • 31.3% vs 13.2% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 23% vs 13.2% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 24.1% vs 9.6% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 22.2% vs 9.6% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 13.3% vs 10.5% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 7.6% vs 10.5% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258
  • 34.1% vs 16% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 31.1% vs 16% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
Roflumilast (Zoryve foam)
50.1% vs 16.8%+33.3 vs placebo0.3% foam · wk 8 · n 281NCT05028582

PASI 90

Roflumilast (Zoryve)
22.4% vs 2.3%+20.1 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 15.5% vs 2% 0.3% cream · wk 8 · n 290 · Phase 3 · secondary NCT04211389
  • 20.6% vs 7.8% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 13.7% vs 7.8% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
  • 16.9% vs 6% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 7.4% vs 6% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 14.3% vs 3.2% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 2.3% vs 3.2% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 6% vs 2.3% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 1.3% vs 2.3% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258
Roflumilast (Zoryve foam)
—Not reported

PASI 100

Roflumilast (Zoryve)
—Not posted · NCT06648772
Roflumilast (Zoryve foam)
—Not reported

sPGA 0/1

Roflumilast (Zoryve)
—Not posted · NCT06648772
Roflumilast (Zoryve foam)
—Not reported

DLQI, change

Roflumilast (Zoryve)
-2.6 vs -1.4−1.2 vs placebo0.3% · wk 12 · n 58NCT03638258
7 other results
  • -4.2 vs -1.4 0.15% · wk 12 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.6 0.3% · wk 8 · n 58 · Phase 2 · secondary NCT03638258
  • -3.5 vs -1.6 0.15% · wk 8 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.8 0.3% · wk 6 · n 58 · Phase 2 · secondary NCT03638258
  • -3.1 vs -1.8 0.15% · wk 6 · n 60 · Phase 2 · secondary NCT03638258
  • -2.2 vs -1.9 0.3% · wk 4 · n 58 · Phase 2 · secondary NCT03638258
  • -2.3 vs -1.9 0.15% · wk 4 · n 60 · Phase 2 · secondary NCT03638258
Roflumilast (Zoryve foam)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Roflumilast (Zoryve): 6 of 6 rows · Roflumilast (Zoryve foam): 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRoflumilast (Zoryve)
Rows use multiple source trials
Roflumilast (Zoryve foam)
Rows use multiple source trials
PASI
absolute change · score
Induction
-68.03 vs -13.65 placebo score @ 12wk0.15%a,b,c,d,e
NCT03638258 · Phase 2 · registry result, not featured evidence
show 1 more dose
-59.48 vs -13.65 placebo score @ 12wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
-2.31 vs -1.03 placebo score @ 2wk0.3% foamb,c,d,e
NCT05028582 · Phase 3
PSD
absolute change · score
Induction
-49.3 vs -22.8 placebo score @ 8wk0.3% creamf,g,d
NCT04211389 · Phase 3
-55 vs -27.5 placebo score @ 8wkf,g,d
NCT04128007 · Phase 2
Dropout rate
10.8%0.3% creamh
NCT04211363 · Phase 3
show 10 more results
9%0.3% cream
NCT04211389 · Phase 3
0%0.3% daily
NCT04746911 · Phase 2 · registry result, not featured evidence
0%0.3% cream
NCT04655313 · Phase 2 · registry result, not featured evidence
28.7%Cohort 1: Study 201 Participants
NCT03764475 · Phase 2 · registry result, not featured evidence
21.6%Cohort 2: Non-study 201 Participan
NCT03764475 · Phase 2 · registry result, not featured evidence
8%0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
—0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.15%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
11%0.3% foamh
NCT05028582 · Phase 3
show 1 more result
11.5%
NCT04128007 · Phase 2
Discontinued due to AEs
1.7%0.3% creamh
NCT04211363 · Phase 3
show 10 more results
0.3%0.3% cream
NCT04211389 · Phase 3
—0.3% daily
NCT04746911 · Phase 2 · registry result, not featured evidence
—0.3% cream
NCT04655313 · Phase 2 · registry result, not featured evidence
4.8%Cohort 1: Study 201 Participants
NCT03764475 · Phase 2 · registry result, not featured evidence
2%Cohort 2: Non-study 201 Participan
NCT03764475 · Phase 2 · registry result, not featured evidence
0%0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
—0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
—0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.15%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
1.8%0.3% foamh
NCT05028582 · Phase 3
show 1 more result
2.5%
NCT04128007 · Phase 2
Serious AEs
0.7%0.3% creamh
NCT04211363 · Phase 3
show 10 more results
0%0.3% cream
NCT04211389 · Phase 3
0%0.3% daily
NCT04746911 · Phase 2 · registry result, not featured evidence
0%0.3% cream
NCT04655313 · Phase 2 · registry result, not featured evidence
3.5%Cohort 1: Study 201 Participants
NCT03764475 · Phase 2 · registry result, not featured evidence
2%Cohort 2: Non-study 201 Participan
NCT03764475 · Phase 2 · registry result, not featured evidence
0.9%0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
0.9%0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0%0.15%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0%0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0.7%0.3% foamh
NCT05028582 · Phase 3
show 1 more result
0.5%
NCT04128007 · Phase 2
Most frequent reported AEs
0.3% dailyh
headache 10%
NCT04746911 · Phase 2 · registry result, not featured evidence
show 8 more results
0.3% cream
application site pain 5%
back pain 5%
candida infection 5%
NCT04655313 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 6.5%
NCT03764475 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 6.9%
NCT03764475 · Phase 2 · registry result, not featured evidence
0.15%
upper respiratory tract infection 6.4% (placebo 0%)
NCT03638258 · Phase 2 · registry result, not featured evidence
0.3%
upper respiratory tract infection 7.3% (placebo 0%)
NCT03638258 · Phase 2 · registry result, not featured evidence
0.5%
candiduria 12.5% (placebo 0%)
application site erythema 0% (placebo 12.9%)
application site pain 0% (placebo 16.1%)
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0.15%
nasopharyngitis 7.1% (placebo 0%)
application site erythema 3.6% (placebo 12.9%)
application site pain 3.6% (placebo 16.1%)
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0.5%
application site erythema 13.3% (placebo 12.9%)
application site pain 6.7% (placebo 16.1%)
nasopharyngitis 6.7% (placebo 0%)
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 12 weeks versus 2 weeks.
  6. fTrial phases differ: Phase 3 versus Phase 2.
  7. gPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
  8. hPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Roflumilast (Zoryve)

IGA 0/1 42.4% (n=255) vs 6.1% (n=132) placebo @ 8wk0.3% cream
responder rate · % of participants
NCT04211363 · Phase 3 · converted to % from 108 Participants as posted
show 1 more result
37.5% (n=264) vs 6.9% (n=131) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 99 Participants as posted
Time to PASI-50 1.02 vs 3.42 placebo months0.3% cream
time to event · months
NCT04211363 · Phase 3 · converted to months from 31 days as posted
show 1 more result
0.99 vs NA placebo months*0.3% cream
NCT04211389 · Phase 3 · converted to months from 30 days as posted
PASI 90 22.4% (n=255) vs 2.3% (n=132) placebo @ 8wk0.3% cream
responder rate · % of participants
NCT04211363 · Phase 3 · converted to % from 57 Participants as posted
show 9 more results
15.5% (n=290) vs 2% (n=152) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 45 Participants as posted
6% (n=109) vs 2.3% (n=109) placebo @ 4wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
1.3% (n=113) vs 2.3% (n=109) placebo @ 4wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
14.3% (n=109) vs 3.2% (n=109) placebo @ 6wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
2.3% (n=113) vs 3.2% (n=109) placebo @ 6wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
16.9% (n=109) vs 6% (n=109) placebo @ 8wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
7.4% (n=113) vs 6% (n=109) placebo @ 8wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
20.6% (n=109) vs 7.8% (n=109) placebo @ 12wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
13.7% (n=113) vs 7.8% (n=109) placebo @ 12wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
I-IGA Clear or Almost Clear 71.2% (n=52) vs 13.8% (n=29) placebo @ 8wk0.3% cream
event count · % of participants
NCT04211363 · Phase 3 · converted to % from 37 Participants as posted
show 1 more result
68.1% (n=47) vs 18.5% (n=27) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 32 Participants as posted
IGA 0 63.5% (n=52) vs 10.3% (n=29) placebo @ 8wk0.3% cream
event count · % of participants
NCT04211363 · Phase 3 · converted to % from 33 Participants as posted
WI-NRS 4-point Reduction 33.5% (n=218) vs 20.9% (n=115) placebo @ 2wk0.3% cream
event count · % of participants
NCT04211363 · Phase 3 · converted to % from 73 Participants as posted
show 2 more results
46.3% (n=218) vs 15.7% (n=115) placebo @ 4wk*0.3% cream
NCT04211363 · Phase 3 · converted to % from 101 Participants as posted
59.2% (n=218) vs 22.6% (n=115) placebo @ 8wk*0.3% cream
NCT04211363 · Phase 3 · converted to % from 129 Participants as posted
I-IGA 0 57.4% (n=47) vs 7.4% (n=27) placebo @ 8wk0.3% cream
event count · % of participants
NCT04211389 · Phase 3 · converted to % from 27 Participants as posted
WI-NRS 4 Improvement 41.9% (n=215) vs 21.1% (n=109) placebo @ 2wk0.3% cream
event count · % of participants
NCT04211389 · Phase 3 · converted to % from 90 Participants as posted
show 2 more results
55.8% (n=215) vs 21.1% (n=109) placebo @ 4wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 120 Participants as posted
66.5% (n=215) vs 33% (n=109) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 143 Participants as posted
IGA Clear or 'Almost Clear 44% (n=209) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 92 Participants as posted
show 15 more results
49.5% (n=95) @ 12wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 47 Participants as posted
37.8% (n=209) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 79 Participants as posted
35.8% (n=95) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
32.5% (n=209) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 68 Participants as posted
37.9% (n=95) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 36 Participants as posted
32.5% (n=209) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 68 Participants as posted
41.1% (n=95) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 39 Participants as posted
28.9% (n=38) @ 12wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
57.7% (n=26) @ 12wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
34.2% (n=38) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
53.8% (n=26) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
34.2% (n=38) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
38.5% (n=26) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
23.7% (n=38) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
38.5% (n=26) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
Duration of Response 1.85 months
time to event · months
No placebo or comparator arm
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to months from 8 weeks as posted
show 1 more result
2.86 months*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to months from 12.4 weeks as posted
PASI 75 29.1% (n=230) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 67 Participants as posted
show 7 more results
61.8% (n=102) @ 12wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 63 Participants as posted
49.6% (n=230) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 114 Participants as posted
55.9% (n=102) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 57 Participants as posted
56.5% (n=230) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 130 Participants as posted
53.9% (n=102) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 55 Participants as posted
53.9% (n=230) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 124 Participants as posted
59.8% (n=102) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 61 Participants as posted
IGA Clear or 'Almost Clear 28% (n=109) vs 8.3% (n=109) placebo @ 6wk0.3%
responder rate · % of participants
NCT03638258 · Phase 2 · registry result, not featured evidence
show 7 more results
22.8% (n=113) vs 8.3% (n=109) placebo @ 6wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
14.5% (n=109) vs 4.4% (n=109) placebo @ 4wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
9% (n=113) vs 4.4% (n=109) placebo @ 4wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
37.9% (n=109) vs 11.9% (n=109) placebo @ 8wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
30.6% (n=113) vs 11.9% (n=109) placebo @ 8wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
37.5% (n=109) vs 16.3% (n=109) placebo @ 12wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
32.1% (n=113) vs 16.3% (n=109) placebo @ 12wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence

+ 7 further endpoints in the CSV export.

Roflumilast (Zoryve foam)

Scalp IGA 66.4% (n=281) vs 27.8% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 3 more results
30.4% (n=281) vs 11.7% (n=151) placebo @ 2wk0.3% foam
NCT05028582 · Phase 3
53.8% (n=281) vs 19.5% (n=151) placebo @ 4wk0.3% foam
NCT05028582 · Phase 3
59.1% (n=181) vs 11.4% (n=88) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 107 Participants as posted
Body IGA 45.5% (n=281) vs 20.1% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 1 more result
40.3% (n=181) vs 6.8% (n=88) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 73 Participants as posted
Scalp Itch NRS 25.2% (n=203) vs 8% (n=123) placebo @ 2wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 5 more results
46.2% (n=203) vs 16.8% (n=123) placebo @ 4wk0.3% foam
NCT05028582 · Phase 3
65.3% (n=203) vs 30.3% (n=123) placebo @ 8wk0.3% foam
NCT05028582 · Phase 3
44.6% (n=166) vs 15.6% (n=90) placebo @ 2wk*
NCT04128007 · Phase 2 · converted to % from 74 Participants as posted
59% (n=166) vs 21.1% (n=90) placebo @ 4wk*
NCT04128007 · Phase 2 · converted to % from 98 Participants as posted
66.3% (n=166) vs 16.7% (n=90) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 110 Participants as posted
Itch NRS -0.44 vs -0.09 placebo score @ 0.14wk0.3% foam
absolute change · score
NCT05028582 · Phase 3
show 2 more results
-1.11 vs -0.36 placebo score @ 0.43wk0.3% foam
NCT05028582 · Phase 3
-1.08 vs -0.53 placebo score @ 1wk0.3% foam
NCT05028582 · Phase 3
Itch NRS 63.1% (n=203) vs 30.1% (n=110) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Itch Pain Scaling -10.87 vs -5.75 placebo score @ 8wk0.3% foam
absolute change · score
NCT05028582 · Phase 3
PSD Itching Score Zero 31.7% (n=274) vs 10% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Pain Score Zero 64.9% (n=274) vs 40.3% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Scaling Score Zero 41.5% (n=274) vs 13.6% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Total Score Zero 19.6% (n=274) vs 7.1% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSSI 75 70.9% (n=281) vs 31.3% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 1 more result
67.2% (n=180) vs 21.8% (n=87) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 121 Participants as posted
IGA 0 40% (n=281) vs 9.1% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Roflumilast (Zoryve)'s landscape · Roflumilast (Zoryve foam)'s landscape